The randomized double-blind, event-driven superiority trial is designed to examine the benefits of the once-daily, oral Factor Xa Inhibitor, rivaroxaban in these patients. Around 7,000 patients will be
The company’s decision was disclosed in its fourth-quarter financial results. According to a filing with the US Securities and Exchange Commission, the drug maker illegally marketed several medicines
MPS IIIB is caused by a decrease in alpha-N-acetyl-glucosaminidase (NAGLU) enzyme activity which leads to the buildup of abnormal amounts of heparan sulfate (HS) in the brain and
The US Food and Drug Administration (FDA) also granted orphan drug designation for ApoCell). Enlivex, a Hadasit Bio-Holdings portfolio company, intends to commence a Phase IIb / III
The open-label, randomized, controlled, global pivotal trial is enrolling patients with advanced primary, not yet treated, head and neck cancer. The trial’s main objective is to show a
OPN-305 is a new humanized IgG4 monoclonal antibody (MAb) against the Toll-Like Receptor 2 (TLR2), a target within the innate immune system. Evaluation of OPN-305 in MDS will
The company acquired Sivextro, as a part of its purchase through a subsidiary of Cubist Pharmaceuticals. Sivextro is a once-daily oxazolidinone antibiotic developed for both intravenous and oral
Alirocumab is an investigational monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). Under the Prescription Drug User Fee Act (PDUFA), the goal for a priority review is
Prestalia is the first fixed-dose combination of perindopril arginine and amlodipine, may be used in patients whose blood pressure is not adequately controlled on monotherapy. The drug may
Assistant professor of biochemistry and molecular biology at Saint Louis University Mee-Ngan F. Yap, Ph.D studied staph that had been treated with the antibiotic azithromycin. During the study
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.